Absci Corporation (Absci (ABSI)) is having a good week. The clinical-stage biopharmaceutical company reported positive interim results from its Phase 1 trial of ABS-201, an antibody designed using artificial intelligence to target the prolactin receptor. And to make sure it has enough cash to keep that momentum going, it also priced a $100 million stock offering. Shares jumped more than 20% in premarket trading on Wednesday, hitting a new 52-week high.

ABS-201 is being developed for two conditions that affect millions of people: androgenetic alopecia (AGA), better known as male or female pattern baldness, and endometriosis, a painful disorder where uterine-like tissue grows outside the uterus. The idea is that blocking the prolactin receptor could help in both diseases, and the early data suggest the drug might be safe enough and last long enough in the body to make that feasible.

The interim data come from the single ascending dose (SAD) portion of the Phase 1 HEADLINE study, a randomized, double-blind, placebo-controlled trial in healthy volunteers with and without AGA. The company reported results from 32 healthy adults across four dose cohorts: 150 mg, 450 mg, 900 mg, and 1,800 mg, all given intravenously.

According to blinded aggregate data through June 8, 2026, ABS-201 was generally well tolerated. No serious adverse events were reported. Most side effects were mild, with the most common being headache (reported in four participants). One participant had a moderate headache that investigators deemed unlikely to be related to the drug. That's about as clean a safety profile as you can hope for at this stage.

Perhaps more interesting is the pharmacokinetic data. ABS-201 appears to have a half-life of at least 65 days. That means it could potentially be dosed only two or three times over six months, which would be a huge convenience advantage over treatments that require daily pills or frequent injections. The company noted that this is subject to confirmation in ongoing follow-up, but it's a promising signal.

The company also reported that anti-drug antibodies didn't seem to affect the drug's pharmacokinetics in the single ascending dose cohorts. That's important because immune responses can sometimes neutralize biologic drugs, making them less effective over time.

With the SAD portion looking good, Absci is moving into the multiple ascending dose (MAD) part of the study in AGA patients. It also plans to start a Phase 2 trial in endometriosis later this year. That's a big deal because endometriosis is a condition with limited treatment options, and a new therapy could be a blockbuster.

To fund all this, Absci announced the pricing of an underwritten offering of 13.5 million shares at $7.41 per share, expected to raise gross proceeds of about $100 million. The company said it will use the net proceeds to advance ABS-201 across both indications, as well as for working capital and other general corporate purposes.

As of March 31, 2026, Absci had $125.7 million in cash, cash equivalents, and marketable securities. That was expected to provide a cash runway into the first half of 2028. The new $100 million should extend that runway significantly, giving the company plenty of time to generate more data and potentially bring ABS-201 to market.

Absci shares were trading at $8.94 in premarket on Wednesday, up 20.65% from the previous close. The stock is now at a new 52-week high, reflecting investor optimism about the AI-designed drug's potential. Whether ABS-201 lives up to that promise will depend on the MAD data and the upcoming Phase 2 trials, but for now, Absci has given investors a reason to be excited.